CDT Equity starts human-skin studies of tapinarof combinations for vitiligo
CDT•CDT Equity has begun preclinical human-skin studies with QIMA Life Sciences to evaluate tapinarof combinations for vitiligo. Positive results would support a licensing package, with the global vitiligo drug market estimated at $2.6 billion in 2025 and projected to reach $6.6 billion by 2030.
1. Studies begin
CDT Equity has begun preclinical human-skin studies with QIMA Life Sciences, using tissue from healthy donors and patients to evaluate its proprietary tapinarof combinations for vitiligo. The company said positive results would underpin a licensing package, and its strategy is to license the combinations to a partner for commercialization.
